American Oncology Network, Inc. (AONC)

American Oncology Network, Inc. (AONC) Healthcare & Pipeline Overview

American Oncology Network, Inc. delivers integrated oncology services across the U.S., offering laboratory, pathology, specialty pharmacy, and care management support. Established in 2017, the Fort Myers-based company aims to provide comprehensive cancer care solutions, positioning itself within the evolving healthcare landscape focused on coordinated patient support.

What Is the Investment Thesis for AONC?

American Oncology Network, Inc. operates within a critical and growing segment of the healthcare market, focusing on comprehensive oncology services. The company's integrated care model, encompassing laboratory, pathology, specialty pharmacy, and care management, positions it to address the multifaceted needs of cancer patients efficiently. With a market capitalization of $292.48M, AONC is a participant in a sector experiencing increasing demand due to rising cancer prevalence and an aging population. Key value drivers include the potential for network expansion across the U.S., leveraging its existing infrastructure and employee base of 1914. While the company currently faces profitability challenges, evidenced by a -0.2% profit margin and a 6.7% gross margin, its integrated approach could drive long-term value by improving patient outcomes and streamlining care delivery. The company's beta of 0.76 suggests relatively lower volatility compared to the broader market. Growth catalysts include strategic acquisitions of oncology practices, enhancement of its specialty pharmacy offerings, and the adoption of advanced diagnostic technologies. Risks include intense competition, evolving healthcare reimbursement policies, and the inherent operational challenges of managing a complex, multi-service healthcare network.

Based on FMP financials and quantitative analysis

AONC Key Highlights

• Market Capitalization: American Oncology Network, Inc. maintains a market capitalization of $292.48M, reflecting its current valuation within the healthcare sector.
• Profit Margin: The company reported a profit margin of -0.2%, indicating that it is currently operating at a net loss relative to its revenue.
• Gross Margin: AONC's gross margin stands at 6.7%, which represents the percentage of revenue left after deducting the cost of goods sold, before accounting for operating expenses.
• Beta: With a beta of 0.76, the stock exhibits lower volatility compared to the overall market, suggesting it is less sensitive to broad market movements.
• Employee Base: The company employs 1914 individuals, underscoring the scale of its operations and its network of oncology services across the United States.

Who Are AONC's Competitors?

AONC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AONC's Key Strengths?

• Integrated model offering comprehensive oncology services, including lab, pathology, specialty pharmacy, and care management.
• Established network and significant employee base (1914) facilitating broad service delivery.
• Patient-centric approach with 24/7 assistance and financial aid programs.
• Focus on a high-demand, critical healthcare segment (oncology).

What Are AONC's Weaknesses?

• Negative profit margin (-0.2%) indicates current operational unprofitability.
• Relatively low gross margin (6.7%) suggests limited pricing power or high cost of services.
• OTC market listing may imply lower liquidity and investor scrutiny compared to major exchanges.
• Reliance on complex healthcare reimbursement models and regulatory compliance.

What Could Drive AONC Stock Higher?

• Strategic expansion into new geographic markets through acquisitions or partnerships, aiming to broaden its patient reach and service network.
• Introduction of advanced diagnostic technologies or specialized treatment modalities within its laboratory and pathology services to enhance clinical offerings.
• Formation of new value-based care contracts with major insurance providers, potentially stabilizing revenue streams and improving profitability.
• Continued growth in the overall demand for comprehensive oncology services driven by an aging population and increasing cancer incidence rates.

What Are the Key Risks for AONC?

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Persistent negative profit margin of -0.2% poses a continuous challenge to the company's financial sustainability and ability to fund future growth initiatives.
• Intense competition within the fragmented oncology services market from larger hospital systems and other specialized providers could pressure market share and pricing.
• Adverse changes in healthcare reimbursement policies or regulatory frameworks could significantly impact revenue streams and operational costs.
• Challenges in attracting and retaining highly skilled oncology professionals and managing the complex logistics of a multi-site healthcare network.
• Risks associated with trading on the 'OTC Other' market, including lower liquidity, limited transparency, and potential for higher price volatility.

What Are the Growth Opportunities for AONC?

• Expansion of Integrated Service Network: American Oncology Network, Inc. has a significant opportunity to expand its network of integrated oncology practices across underserved or growing geographic markets within the United States. By acquiring or partnering with additional community oncology clinics, AONC can extend its reach, increase patient access to its comprehensive services, and achieve greater economies of scale. The U.S. cancer care market is estimated to be hundreds of billions of dollars annually and continues to grow, providing a substantial addressable market for network expansion over the next 5-10 years, particularly in regions with high population growth or limited specialized oncology resources.
• Enhancement of Specialty Pharmacy Services: The demand for specialty pharmacy services, particularly in oncology, is rapidly increasing due to the complexity and high cost of cancer medications. AONC can capitalize on this by further enhancing its in-house specialty pharmacy offerings, including expanding its formulary, improving patient adherence programs, and leveraging technology for medication management. This segment offers high-margin potential and strengthens patient retention within the AONC ecosystem. The global specialty pharmacy market is projected to reach over $1 trillion by 2030, indicating a robust growth trajectory for this service line over the medium to long term.
• Advanced Diagnostic and Pathology Services: Investing in and integrating cutting-edge diagnostic and pathology technologies presents a significant growth avenue. This includes molecular diagnostics, genomic profiling, and advanced imaging techniques that enable more precise cancer diagnosis and personalized treatment plans. By offering these advanced services in-house, AONC can attract more patients and referring physicians, improve treatment efficacy, and potentially reduce outsourcing costs. The market for cancer diagnostics alone is projected to exceed $250 billion by 2030, offering substantial growth for AONC's specialized laboratory and pathology capabilities over the next 3-7 years.
• Telehealth and Remote Patient Monitoring Integration: Leveraging telehealth and remote patient monitoring solutions can significantly enhance AONC's care management support, particularly for patients in rural areas or those with mobility challenges. Implementing virtual consultations, remote symptom monitoring, and digital patient education platforms can improve patient convenience, reduce hospital readmissions, and optimize resource utilization. This aligns with broader healthcare trends towards digital transformation and patient-centric care. The global telehealth market is expected to grow substantially, reaching hundreds of billions by 2030, creating a strong opportunity for AONC to expand its virtual care offerings over the next 2-5 years.
• Adoption of Value-Based Care Models: The healthcare industry is increasingly shifting towards value-based care models, which incentivize providers for patient outcomes rather than the volume of services. AONC's integrated service model is inherently well-suited for these models, as it allows for coordinated care, better cost management, and improved patient results. By actively participating in and developing value-based contracts with payers, AONC can secure more stable revenue streams and demonstrate its commitment to quality care, potentially leading to increased market share and profitability over the long term, typically within a 3-10 year horizon as these models mature.

What Opportunities Does AONC Have?

• Expansion of its integrated network into new geographic markets to capture growing demand for cancer care.
• Further enhancement and technological integration within specialty pharmacy and diagnostic services.
• Strategic partnerships or acquisitions to broaden service offerings or market reach.
• Leveraging telehealth and remote monitoring to improve patient access and care efficiency.

What Threats Does AONC Face?

• Intense competition from other large hospital systems, independent practices, and specialized oncology providers.
• Potential for adverse changes in healthcare reimbursement policies and regulations.
• Economic downturns impacting patient ability to pay or insurance coverage.
• Challenges in attracting and retaining highly specialized oncology professionals.
• Operational risks associated with managing a complex, multi-service healthcare network.

What Are AONC's Competitive Advantages?

• Integrated Service Offering: Provides a comprehensive suite of oncology services (lab, pathology, pharmacy, care management) under one network, simplifying patient care pathways.
• Patient-Centric Support: Emphasis on 24/7 patient assistance, financial aid, and nutrition guidance creates a supportive environment that can enhance patient loyalty.
• Network Scale: A significant employee base of 1914 suggests an established operational footprint and capacity to serve a broad patient population.
• Specialized Expertise: Focus solely on oncology allows for deep specialization and expertise in cancer diagnosis, treatment, and management.

What Does AONC Do?

American Oncology Network, Inc. (AONC), established in 2017 and headquartered in Fort Myers, Florida, operates as a comprehensive provider of oncology services throughout the United States. The company's core mission revolves around delivering an integrated approach to cancer care, ensuring patients receive a broad spectrum of support services under one network. AONC's service offerings are designed to cover critical aspects of cancer treatment and patient well-being. This includes robust laboratory services, which provide both routine and specialized testing essential for accurate diagnosis, treatment planning, and monitoring patient progress. Complementing this, AONC offers in-house professional and technical pathology services, ensuring that tissue samples are analyzed with precision and that complete, accurate, and timely pathology reports are generated to guide clinical decisions. A significant component of its integrated model is the in-house specialty pharmacy services. This service goes beyond merely dispensing medication, providing crucial patient education, assisting with financial aid programs to alleviate cost burdens, and offering 24/7 patient assistance to address urgent needs and medication-related inquiries. Furthermore, the company emphasizes holistic patient support through its care management services, which include vital nutrition guidance, recognizing the critical role of diet in cancer recovery and overall patient health. With a workforce of 1914 employees, American Oncology Network, Inc. has built a substantial operational footprint aimed at enhancing the quality and accessibility of oncology care by integrating various specialized services into a cohesive patient journey.

What Products and Services Does AONC Offer?

• Provides comprehensive oncology services across the United States.
• Offers in-house laboratory services for routine and specialized testing.
• Delivers professional and technical pathology services with timely reporting.
• Operates in-house specialty pharmacy services, including patient education and financial assistance.
• Provides 24/7 patient assistance through its specialty pharmacy.
• Offers care management support services, including nutrition guidance.
• Focuses on an integrated approach to cancer care for patients.
• Manages a network of oncology practices and services.

How Does AONC Make Money?

• Generates revenue through fees for laboratory and pathology diagnostic services.
• Earns income from the dispensing of specialty pharmaceuticals through its in-house pharmacy.
• Receives reimbursement for professional medical services provided by its network of oncologists.
• Provides care management and support services, which may be reimbursed through bundled payments or specific service codes.

What Industry Does AONC Operate In?

American Oncology Network, Inc. operates within the U.S. medical care facilities industry, specifically focusing on oncology services, a segment characterized by increasing demand driven by rising cancer incidence rates and an aging population. The broader healthcare sector is experiencing a shift towards integrated care models that aim to improve patient outcomes and cost-efficiency. AONC's strategy of providing comprehensive services—from diagnostics and pathology to specialty pharmacy and care management—positions it within this trend. The competitive landscape for oncology services is fragmented, comprising large hospital systems, independent oncology practices, and other specialized providers. AONC differentiates itself by offering a unified network of services, aiming to provide a seamless patient experience. The market for cancer care is substantial and projected to grow, with a continuous need for advanced treatments and supportive care, making the ability to scale and integrate services a key competitive factor.

Who Are AONC's Key Customers?

• Cancer patients seeking comprehensive diagnostic, treatment, and supportive care.
• Oncology practices and physicians looking to integrate into a larger network for administrative and clinical support.
• Healthcare payers (insurance companies, government programs) seeking efficient and coordinated cancer care delivery.
• Families and caregivers of cancer patients who benefit from integrated support services.

American Oncology Network, Inc. (AONC) Valuation Context

Valued at $292.48M, AONC is classified as a micro-cap stock. Relative to its peer group, AONC's quantitative score of 50/100 is below the peer average of 60/100.

AONC Revenue & Earnings Trend

In Q4 2024, AONC generated $490.9M in top-line revenue, marking a sequential increase of 4.4%. The company recorded net income of $1.3M, with diluted EPS of $-0.00. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, AONC averaged $-0.34 in diluted EPS.

Company Profile

American Oncology Network, Inc. operates in the Medical - Care Facilities industry within the Healthcare sector. It is headquartered in Fort Myers, US. The company is led by CEO Todd Schonherz. AONC has traded publicly since 2021.

ROE 6%Key Financial Metrics

Return on equity for American Oncology Network, Inc. stands at 5.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.53 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 3/9Financial Health

American Oncology Network, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.09 places it in the safe zone, indicating low near-term bankruptcy risk.

AONC Financials

AONC Latest News

AONC Analyst Consensus

AONC MoonshotScore

American Oncology Network, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources